Eluminex is dedicated towards developing first- and/or best-in-class protein therapeutics to enhance people lives and become a global leader in collagen-based aesthetics/ regenerative medicine and treatment for vision threatening diseases.
Eluminex Biosciences is a privately-held biotechnology company founded in early 2020. The leadership team comprises over 150 years of cumulative global product development with a longstanding track record of success in both pharmaceuticals and medical devices. Our company headquarters, research and development (R&D) center, and Good Manufacturing Practices (GMP) manufacturing facilities are located in Suzhou BioBAY, China and our US regional office is located in Mountain View, California, in the heart of Silicon Valley.
We have established a state-of-the-art R&D and two fully activated GMP manufacturing facilities in the Suzhou BioBAY. The R&D center includes a GMP manufacturing facility for our collagen-based programs as well as support for basic science research, drug discovery, formulation development, and validating preclinical/chemistry, manufacturing, and control (CMC) studies for investigational new drug (IND) and premarket approval (PMA) submissions in both China and the United States. Our second GMP manufacturing facility is the center piece of our regenerative medicine/aesthetics platform – the first dedicated GMP facility in the world for the exclusive production of full-length, triple helix recombinant human Type III collagen (rhCIII).
Look better. See better.
Message from the CEO
2023 was a major year of tremendous progress for Eluminex Biosciences. First, we successfully secured additional resources with completion of Series B/ B+ round of financing in September 2023, raising a cumulative total of over $100 million (USD) since the company’s inception in 2020. These funds provide significant momentum for us to solidify our leadership in the development of advanced engineered proteins into the clinic and have enabled us to expand our portfolio into two major businesses: Eluminex Aesthetics and Eluminex Ophthalmics. The core of our emerging aesthetics pipeline is the production of full length, triple helix recombinant human type III collagen (rhCIII), a key dermal protein whose natural production progressively declines as we age – leading to facial fine lines and wrinkles and loss of skin elasticity. Our rhCIII will now be the center-piece of a portfolio of injectable aesthetics to enhance skin quality. We currently are the only company in the world with production capabilities to product full-length triple helix rhCIII.
Secondly, I am pleased to report that we have recently completed our physical plant and R&D expansion (total ~ 60,000 sft; ~ 5600 sqm) with activation of two dedicated GMP facilities in Suzhou BioBAY, designed to produce rhCIII and medical aesthetic products at commercial scale; these facilities are wholly owned and operated by Eluminex Biosciences.
Lastly, I am also proud to report that Eluminex Ophthalmics has developed a portfolio of next generation therapies for ophthalmic diseases, including tri-specific antibodies via intravitreal injection for vision-threatening retinal disease and bi-specific antibodies through systemic delivery for thyroid eye disease. EB-105, a fusion antibody will be the first tri-specific antibody in the world to be introduced into the clinic in 2024 for diabetic macular edema – a leading cause of vision-loss worldwide.
2024 holds promise to be an inflection point for Eluminex. Our overall goal remains to make a difference for people around the world who can benefit from our unique pipeline of recombinantly-engineered human proteins to enhance people’s lives. We are truly proud of our mission – to help people look better and see better.
Jinzhong (JZ) Zhang, PhD
FOUNDER, CHAIRMAN, AND CEO
Eluminex Receives Multiple Awards for Innovation in 2023
Eluminex received multiple major awards in 2023. On December 19, 2023, Eluminex Biosciences was recognized as a potential “unicorn” biotechnology company by the Hurun Research Institute. The Institute’s Global Cheetah Enterprise List identified 747 high-growth global companies most likely to reach unicorn-level valuation of > 1 billion USD within five years that included Eluminex along with 291 other China-based companies.
On October 19, 2023, Eluminex received the “Synthetic Biology Rising Star Enterprise” award in Shanghai for its work in synthetic biology.
On August 18, 2023, the Haoyue Capital announced the Seventh Annual Excellent Healthcare Investment List and Eluminex Biosciences was named as the “Best Innovative Pharmaceutical Company of the Year”.